Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Location: Canada, Montreal (06), Montreal
Employees: 11-50
Total raised: $11M
Founded date: 2014
Investors 2
| Date | Name | Website |
| 27.10.2023 | Genesys Ca... | genesyscap... |
| - | Anges Québ... | angesquebe... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.05.2021 | Seed | $11M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 21.05.2021 | Giiant Pharma Closes US$11M Seed Funding | Giiant Pharma Inc., a Montreal, Canada based preclinical-stage biotech company, raised US$11M in see... | finsmes.co... |
| 21.05.2021 | Giiant Pharma Inc Announced the Closing of US$11m in Seed Fi... | Giiant Pharma inc., a Montreal-based preclinical-stage biotech company, today announced the closing ... | marketscre... |